{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:50:53Z","timestamp":1793659853239,"version":"4.5.1"},"reference-count":189,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016694","name":"Science and Technology Development Plan of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH372"],"award-info":[{"award-number":["ZR2022QH372"]}],"id":[{"id":"10.13039\/100016694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lung cancer continues to be the leading cause of cancer-related mortality worldwide, accounting for more deaths than breast, colorectal, and prostate cancers combined. Over the past decade, the introduction of immunotherapy has reshaped treatment paradigms, offering hope for long-term survival in a disease historically associated with dismal outcomes. The incorporation of immune checkpoint inhibitors (ICIs) into the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has improved outcomes across early-stage, locally advanced, and metastatic settings. However, only a fraction of patients derive durable benefit, and challenges remain in overcoming resistance, predicting response, managing toxicity, and ensuring equitable access. This review provides a comprehensive overview of current progress in lung cancer immunotherapy. It discusses the immunobiology of lung tumors, the role of checkpoint blockade across disease stages, mechanisms of resistance, biomarker development, and combination strategies. Emerging modalities, including bispecific antibodies, CAR- and TCR-based cellular therapies, natural killer (NK) cell platforms, cytokine agonists, oncolytic viruses, and vaccines, are explored in depth. We also evaluate the translational significance of preclinical models, toxicity management, and issues of equity and accessibility. Finally, we outline key future directions that may redefine lung cancer immunotherapy in the coming years. Collectively, these advances highlight a transition from broad applications of checkpoint inhibition toward stage-specific, biomarker-driven, and multimodal immunotherapy approaches designed to convert temporary responses into durable remissions and, ultimately, cures.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1728163","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:31:45Z","timestamp":1768545105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Lung cancer immunotherapy in 2025: where we stand and what comes next?"],"prefix":"10.3389","volume":"16","author":[{"given":"Jie","family":"Han","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Lanzhou University Second Hospital, Lanzhou","place":["Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, 3201 Hospital of Xi\u2019an Jiaotong University Health Science Center","place":["Hanzhong, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01245-w","article-title":"Small cell lung cancer\u2014an update on chemotherapy resistance","volume":"25","author":"Ying","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non\u2013small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01926-4","article-title":"Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1\/PD-L1 blockade in the clinical spectrum of lung cancer","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e009667","DOI":"10.1136\/jitc-2024-009667","article-title":"New developments in immunotherapy for SCLC","volume":"13","author":"Dolkar","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-025-00992-5","article-title":"The current and emerging immunotherapy paradigm in small-cell lung cancer","volume":"6","author":"Qin","year":"2025","journal-title":"Nat Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.09.011","article-title":"Antigen-presenting cells as specialized drivers of intestinal T cell functions","volume":"57","author":"Kedmi","year":"2024","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e15472","DOI":"10.1111\/tan.15472","article-title":"Assessment of cancer cell-expressed HLA class I molecules and their immunopathological implications","volume":"103","author":"Kubo","year":"2024","journal-title":"HLA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512509","article-title":"The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41698-024-00665-z","article-title":"Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities","volume":"8","author":"Lozac\u2019hmeur","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107361","DOI":"10.1016\/j.lungcan.2023.107361","article-title":"Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-) mutations in non-small cell lung cancer with a special focus on KRAS G12C","volume":"184","author":"Boeschen","year":"2023","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"201185","DOI":"10.1016\/j.humgen.2023.201185","article-title":"MYC and non-small cell lung cancer: A comprehensive review","volume":"37","author":"Kenzerki","year":"2023","journal-title":"Hum Gene"},{"key":"B20","first-page":"376","article-title":"Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer","volume":"4","author":"Quatromoni","year":"2012","journal-title":"Am J Transl Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9566-0","article-title":"Regulatory T cells and potential inmmunotherapeutic targets in lung cancer","volume":"34","author":"Zhang","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.6RU0918-353RRRR","article-title":"The expanding family of noncanonical regulatory cell subsets","volume":"106","author":"Zhao","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1614731","article-title":"Dissecting the intratumoral microbiome landscape in lung cancer","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582532","article-title":"Revisiting the role of cancer-associated fibroblasts in tumor microenvironment","volume":"16","author":"Lan","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182435f3e","article-title":"Tumor vasculature as a therapeutic target in non-small cell lung cancer","volume":"7","author":"Bar","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0260988","DOI":"10.1371\/journal.pone.0260988","article-title":"Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer","volume":"16","author":"Rice","year":"2021","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102606","DOI":"10.1016\/j.ctrv.2023.102606","article-title":"Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1002\/mco2.343","article-title":"Hot and cold tumors: Immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100627","DOI":"10.1016\/j.jtocrr.2023.100627","article-title":"Genomic Landscape of NSCLC in the Republic of IRELAND","volume":"5","author":"Keogh","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac094","article-title":"Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases","volume":"27","author":"Huang","year":"2022","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-025-03530-z","article-title":"Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases","volume":"31","author":"Tagore","year":"2025","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger","year":"2024","journal-title":"Oncologist"},{"key":"B36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41698-024-00552-7","article-title":"BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape","volume":"8","author":"Planchard","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"104234","DOI":"10.1016\/j.critrevonc.2023.104234","article-title":"Oncogenic fusions: targeting NTRK","volume":"194","author":"Hagopian","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00432-025-06115-y","article-title":"Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer","volume":"151","author":"Wang","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000500","article-title":"Clinical outcomes of PD-1\/PD-L1 inhibitors among patients with advanced or metastatic non\u2013small cell lung cancer with BRAF, ERBB2\/HER2, MET, or RET alterations: a systematic literature review","volume":"47","author":"Akers","year":"2024","journal-title":"J Immunother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2441499","DOI":"10.1080\/15384047.2024.2441499","article-title":"First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives","volume":"26","author":"He","year":"2025","journal-title":"Cancer Biol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.06.011","article-title":"KEAP1 and STK11\/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer","volume":"43","author":"Galan-Cobo","year":"2025","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1684089","article-title":"Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations","volume":"16","author":"Nie","year":"2025","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01037-4","article-title":"Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc","volume":"6","author":"Wang","year":"2024","journal-title":"Nat Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401528","article-title":"From mechanism to therapy: the journey of CD24 in cancer","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D\u2019incecco","year":"2015","journal-title":"Br J Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-014-0305-5","article-title":"Immune checkpoint inhibitors in NSCLC","volume":"15","author":"Johnson","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.01.020","article-title":"The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Wang","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1631800","article-title":"The role of combination chemo-immunotherapy in advanced non-small cell lung cancer","volume":"19","author":"Rocco","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1808567","article-title":"Pembrolizumab plus chemotherapy in lung cancer","volume":"379","author":"Gil-Sierra","year":"2018","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non\u2013small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.3390\/cancers12123707","article-title":"Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a \u2018real-life\u2019setting","volume":"12","author":"Skribek","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC\u2014an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00794-7","article-title":"Immune-checkpoint inhibition for resectable non-small-cell lung cancer\u2014Opportunities and challenges","volume":"20","author":"Mountzios","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2024.01.024","article-title":"The emerging role of immunotherapy in resectable non-small cell lung cancer","volume":"118","author":"Dunne","year":"2024","journal-title":"Ann Thorac Surg"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/cancers16091619","article-title":"Neoadjuvant and adjuvant immunotherapy in resectable NSCLC","volume":"16","author":"Bogatsa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/LCTT.S277717","article-title":"Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer","volume":"28","author":"Shukla","year":"2021","journal-title":"Lung Cancer Targets Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B64","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2024.09.608","article-title":"P3. 08F. 02 MRD guiding treatment after aumolertinib induction therapy for EGFRm+ Stage III NSCLC in the MDT diagnostic model (APPROACH)","volume":"19","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC\u2014challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1200\/JCO.2024.42.16_suppl.8078","article-title":"Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)","volume":"42","author":"Isbell","year":"2024","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"115237","DOI":"10.1016\/j.ejca.2025.115237","article-title":"Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer","volume":"217","author":"Hong","year":"2025","journal-title":"Eur J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30100640","article-title":"Fluctuation of acquired resistance mutations and re-challenge with EGFR TKI in metastatic NSCLC: a case report","volume":"30","author":"Falk","year":"2023","journal-title":"Curr Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00432-020-03362-z","article-title":"Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)","volume":"147","author":"Ma","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"705","DOI":"10.21037\/atm-21-1423","article-title":"Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Niu","year":"2021","journal-title":"Ann Transl Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.3390\/cells9112393","article-title":"Tumour PD-L1 expression in small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Acheampong","year":"2020","journal-title":"Cells"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.013","article-title":"PD-L1 expression in small cell lung cancer","volume":"13","author":"Yasuda","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","article-title":"IL-18\u2013secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2293","article-title":"Allogeneic CAR T cells targeting DLL3 are efficacious and safe in preclinical models of small cell lung cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"694","DOI":"10.21037\/tlcr-23-820","article-title":"DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges","volume":"13","author":"Bellis","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1433","article-title":"Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer","volume":"83","author":"Chou","year":"2023","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105603","article-title":"DLL3 regulates Notch signaling in small cell lung cancer","volume":"25","author":"Kim","year":"2022","journal-title":"IScience"},{"key":"B83","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B84","first-page":"23","article-title":"Drug resistance in lung cancer","volume":"8","author":"Shanker","year":"2010","journal-title":"Lung Cancer Targets Ther"},{"key":"B85","first-page":"189","article-title":"Chemotherapy resistance in lung cancer","volume":"893","author":"Kim","year":"2015","journal-title":"Lung Cancer Pers Med Curr Knowl Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.05.010","article-title":"Resisting resistance: targeted therapies in lung cancer","volume":"2","author":"Lin","year":"2016","journal-title":"Trends Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"741741","DOI":"10.1155\/2012\/741741","article-title":"Tumor-induced CD8+ T-cell dysfunction in lung cancer patients","volume":"2012","author":"Prado-Garcia","year":"2012","journal-title":"J Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2022.05.026","article-title":"Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer","volume":"172","author":"Rosellini","year":"2022","journal-title":"Eur J Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","article-title":"Clinical implications of KEAP1-NFE2L2 mutations in NSCLC","volume":"16","author":"Hellyer","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2017.07.030","article-title":"MHC class II expression in lung cancer","volume":"112","author":"He","year":"2017","journal-title":"Lung Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"107522","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1542142","article-title":"The microbial landscape of tumors: a deep dive into intratumoral microbiota","volume":"16","author":"Asgharzadeh","year":"","journal-title":"Front Microbiol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.3390\/ijms26094096","article-title":"New therapeutic targets TIGIT, LAG-3 and TIM-3 in the treatment of advanced, non-small-cell lung cancer","volume":"26","author":"Kabut","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B95","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.019","article-title":"Lactate metabolism in human lung tumors","volume":"171","author":"Faubert","year":"2017","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1320244","article-title":"Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-016-9536-3","article-title":"A new algorithm for a better characterization and timing of the anti-VEGF vascular effect named \u201cnormalization","volume":"20","author":"El Alaoui-Lasmaili","year":"2017","journal-title":"Angiogenesis"},{"key":"B99","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12951-024-02584-4","article-title":"Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications","volume":"22","author":"Tong","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190716112319","article-title":"Therapeutic potential of agonists and antagonists of A1, A2a, A2b and A3 adenosine receptors","volume":"25","author":"Jamwal","year":"2019","journal-title":"Curr Pharm Des"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00383-9","article-title":"The KRAS-G12C inhibitor: activity and resistance","volume":"29","author":"Liu","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 expression in lung cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non\u2013small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"639","DOI":"10.21037\/tlcr.2018.10.08","article-title":"The clinical utility of tumor mutational burden in non-small cell lung cancer","volume":"7","author":"Greillier","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102017","article-title":"Interferon-\u03b3-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer","volume":"6","author":"Cao","year":"2025","journal-title":"Cell Rep Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-025-13484-7","article-title":"The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of lung cancer patients: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e70523","DOI":"10.1002\/cam4.70523","article-title":"Exploring Multiplex Immunohistochemistry (mIHC) techniques and Histopathology image analysis: Current practice and potential for clinical incorporation","volume":"14","author":"Sun","year":"2025","journal-title":"Cancer Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"De Zuani","year":"2024","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/cancers17121912","article-title":"Spatial transcriptomics in lung cancer and pulmonary diseases: A comprehensive review","volume":"17","author":"Kang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.4c00606","article-title":"Recent advancements in the application of circulating tumor DNA as biomarkers for early detection of cancers","volume":"10","author":"Mishra","year":"2024","journal-title":"ACS Biomater Sci Eng"},{"key":"B112","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/cancers16050940","article-title":"ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer","volume":"16","author":"Desai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e2400160","DOI":"10.1200\/CCI-24-00160","article-title":"Early circulating tumor DNA kinetics as a dynamic biomarker of cancer treatment response","volume":"9","author":"Li","year":"2025","journal-title":"JCO Clin Cancer Inf"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e2400291","DOI":"10.1200\/CCI-24-00291","article-title":"Optimizing strategy for lung cancer screening: from risk prediction to clinical decision support","volume":"9","author":"Dai","year":"2025","journal-title":"JCO Clin Cancer Inf"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e005539","DOI":"10.1136\/jitc-2022-005539","article-title":"Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer","volume":"11","author":"He","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1422206","article-title":"Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring","volume":"15","author":"Berthe","year":"2024","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.11.001","article-title":"The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma","volume":"174","author":"Tamiya","year":"2022","journal-title":"Lung Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3390\/cancers15041068","article-title":"Transbronchial techniques for lung cancer treatment: where are we now","volume":"15","author":"Chan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700756","article-title":"Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer","volume":"11","author":"Ito","year":"2004","journal-title":"vivo. Cancer Gene Ther"},{"key":"B121","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.620374","article-title":"Dendritic cell-based immunotherapy in lung cancer","volume":"11","author":"Stevens","year":"2021","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.08.012","article-title":"The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/cells12242801","article-title":"The complex role of the microbiome in non-small cell lung cancer development and progression","volume":"12","author":"Souza","year":"2023","journal-title":"Cells"},{"key":"B126","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41579-024-01048-8","article-title":"The gut\u2013airway microbiome axis in health and respiratory diseases","volume":"22","author":"\u00d6z\u00e7am","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109893","article-title":"Unveiling the intratumoral microbiota within cancer landscapes","volume":"27","author":"Che","year":"2024","journal-title":"Iscience"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1497173","article-title":"Bacteria and fungi of the lung: allies or enemies","volume":"15","author":"Garaci","year":"2024","journal-title":"Front Pharmacol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41564-023-01546-0","article-title":"Candida albicans extracellular vesicles trigger type I IFN signalling via cGAS and STING","volume":"9","author":"Brown Harding","year":"2024","journal-title":"Nat Microbiol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41575-025-01100-9","article-title":"Credible inferences in microbiome research: ensuring rigour, reproducibility and relevance in the era of AI","volume":"22","author":"Caminero","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0897","article-title":"Immunotherapy with or without chemotherapy in advanced NSCLC\u2014A delicate balance of harm and benefit","volume":"11","author":"Mountzios","year":"2025","journal-title":"JAMA Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221113268","article-title":"Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial","volume":"14","author":"Remon","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/cancers13061468","article-title":"Charged particle and conventional radiotherapy: current implications as partner for immunotherapy","volume":"13","author":"Marcus","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B134","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.7150\/thno.97768","article-title":"Biomarker-driven molecular imaging probes in radiotherapy","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663612","article-title":"The impact of VEGF inhibition on clinical outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective cohort study","volume":"11","author":"Tanimura","year":"2021","journal-title":"Front Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","first-page":"eaaw7999","DOI":"10.1126\/scitranslmed.aaw7999","article-title":"Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer","volume":"11","author":"Molina-Arcas","year":"2019","journal-title":"Sci Transl Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e004089","DOI":"10.1136\/jitc-2021-004089","article-title":"Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy","volume":"10","author":"Augustin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11912-017-0634-1","article-title":"CSF-1R inhibitor development: current clinical status","volume":"19","author":"Peyraud","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-20-32","article-title":"Clinical development of colony-stimulating factor 1 receptor (CSF1R) inhibitors","volume":"4","author":"Lin","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12964-024-01586-x","article-title":"Role of STING in the treatment of non-small cell lung cancer","volume":"22","author":"Tang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.heliyon.2024.e24729","article-title":"Current state of immune checkpoints therapy for glioblastoma","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"B144","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","article-title":"TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies","volume":"16","author":"Cui","year":"2025","journal-title":"Cell Death Dis"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT051","article-title":"Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC","volume":"85","author":"Peters","year":"2025","journal-title":"Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.682","article-title":"EP08.01\u2013110 trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in mNSCLC","volume":"17","author":"Chesney","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2024.100251","article-title":"CRISPR\/Cas9: Role of genome editing in cancer immunotherapy","volume":"10","author":"Vimal","year":"2024","journal-title":"Oral Oncol Rep"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062365","article-title":"Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells","volume":"14","author":"Kim","year":"2023","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.164320","article-title":"CRISPR\/Cas9-mediated metabolic engineering for enhanced PUFA production in Schizochytrium limacinum","volume":"517","author":"Duan","year":"2025","journal-title":"Chem Eng J"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2024.103601","article-title":"Generation of a homozygous TIGIT gene knockout (TIGIT\u2013\/\u2013) human iPSC line (MUSIi001-A-3) using CRISPR\/Cas9 system","volume":"81","author":"Srisantitham","year":"2024","journal-title":"Stem Cell Res"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.jtocrr.2023.100630","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.heliyon.2023.e21776","article-title":"CAR-T cell therapy for hematological Malignancies: History, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122556","article-title":"CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases","volume":"344","author":"Yang","year":"2024","journal-title":"Life Sci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1492552","article-title":"Chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102199","article-title":"EGFR TKIs suppress MUC1 glycosylation through the PI3K\/AKT\/SP1\/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13046-024-03015-w","article-title":"Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET","volume":"43","author":"Xia","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"155947","DOI":"10.1016\/j.prp.2025.155947","article-title":"CAR T cells in lung cancer: Targeting tumor-associated antigens to revolutionize immunotherapy","volume":"269","author":"Alenezi","year":"2025","journal-title":"Pathol Pract"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41590-025-02252-1","article-title":"TCR-engineered T cells targeting a shared \u03b2-catenin mutation eradicate solid tumors","volume":"26","author":"Eggeb\u00f8","year":"2025","journal-title":"Nat Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12885-025-13780-2","article-title":"CAR-NK cells with dual targeting of PD-L1 and MICA\/B in lung cancer tumor models","volume":"25","author":"Zhi","year":"2025","journal-title":"BMC Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"465","DOI":"10.17305\/bb.2023.9675","article-title":"CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar","volume":"24","author":"Chen","year":"2024","journal-title":"Biomol BioMed"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01578","article-title":"Tregs: Where we are and what comes next","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.21037\/tlcr-2024-1097","article-title":"Towards the development of next-generation lung cancer immunotherapy","volume":"14","author":"Ichiki","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B171","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B172","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat Commun"},{"key":"B173","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s43556-024-00222-x","article-title":"Prophylactic and therapeutic vaccine development: advancements and challenges","volume":"5","author":"Weerarathna","year":"2024","journal-title":"Mol BioMed"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases\u2014advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B175","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.1038\/s41467-024-51411-9","article-title":"Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site","volume":"15","author":"Kim","year":"2024","journal-title":"Nat Commun"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02929-7","article-title":"Genetically-engineered mouse models of small cell lung cancer: the next generation","volume":"43","author":"Oser","year":"2024","journal-title":"Oncogene"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.28.582577","article-title":"A lung cancer mouse model database","author":"Cai","year":"2024","journal-title":"bioRxiv"},{"key":"B179","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1038\/s41467-024-47547-3","article-title":"Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models","volume":"15","author":"Hynds","year":"2024","journal-title":"Nat Commun"},{"key":"B180","doi-asserted-by":"publisher","first-page":"100781","DOI":"10.1016\/j.jtocrr.2024.100781","article-title":"Humanized mouse models for immuno-oncology research: a review and implications in lung cancer research","volume":"6","author":"Park","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B181","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170503","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","volume":"134","author":"Ghanbar","year":"2024","journal-title":"J Clin Invest"},{"key":"B184","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1004625","article-title":"Endocrine adverse events in cancer immunotherapy: from mechanisms to clinical practice","author":"Aseyev","year":"2024","journal-title":"Adv Cancer Immunother IntechOpen"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e13575","article-title":"Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS)","volume":"42","author":"Donnellan","year":"2024"},{"key":"B187","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol Cancer"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/cancers17081347","article-title":"Equity and opportunities in lung cancer care\u2014Addressing disparities, challenges, and pathways forward","volume":"17","author":"Shehata","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B189","article-title":"Nanotechnology Based Strategies for Cancer Immunotherapy: Concepts, Design, and Clinical Applications","author":"Sharma","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1728163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:56:35Z","timestamp":1771916195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1728163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":189,"alternative-id":["10.3389\/fimmu.2025.1728163"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1728163","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1728163"}}